Both approaches have shown potential to significantlyenhance patient outcomes, and ongoing research continues to explorecombining them for even more effective and personalized cancer treatments.In this study, we discovered a series of promising MER/AXL inhibitorspossessed a furanopyrimidine scaffold that exhibited excellent immunomodulatoryeffects and effective antitumor efficacy in murine syngeneic and xenografttumor models. The gene discussed is AXL; the disease is cancer.